OPEN END TURBO LONG - BRISTOL-MYERS SQUIBB | Market Closed - Börse Stuttgart 03:44:48 2024-07-16 pm EDT | ||
| 0.209 EUR | +75.63% |
|
| Current month | -16.40% | ||
| 1 month | -13.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.209 | +75.63% |
| 24-07-15 | 0.119 | -29.59% |
| 24-07-12 | 0.169 | -5.59% |
| 24-07-11 | 0.179 | -19.37% |
| 24-07-10 | 0.222 | +16.84% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 03:44 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Morgan Stanley |
| WKN | ME3DJ2 |
| ISIN | DE000ME3DJ21 |
| Date issued | 2023-11-09 |
| Strike | 38.85 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.48 € |
|---|---|
| Lowest since issue | 0.084 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
52.69
USD
Spread / Average Target
+27.90%
- Stock Market
- Certificates
- Certificat
